/

Società

As

Non verificato

AstraZeneca

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

123 comunicati stampa

Guarda tutti i comunicati

08/09/2026

Industria

Scienza

Medicina - Varie

Sanità

Biotecnologia

Farmaceutica

Salute

Oncologia

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

Fonte

Emittente

1.00

0

08/09/2026

Eventi

Industria

Biotecnologia

Sanità

Salute

Farmaceutica

Medicina - Varie

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

Fonte

Emittente

1.00

0

04/09/2026

Industria

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Farmaceutica

Vetrine/Shopping

Salute

Oncologia

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

Fonte

Emittente

1.00

0

01/09/2026

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

Fonte

Emittente

1.00

0

27/08/2026

Industria

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints

Fonte

Emittente

1.00

0

17/08/2026

Industria

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

Fonte

Emittente

1.00

0

17/08/2026

Industria

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

Fonte

Emittente

1.00

0

27/07/2026

Industria

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Fonte

Emittente

1.00

0

27/07/2026

Web e Social Network

Mercato del lavoro

Telefonia e Varie

Mercato azionario

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

AstraZeneca results: H1 and Q2 2026

Fonte

Emittente

1.00

0

24/06/2026

Mercato del lavoro

Industria

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0